Immunovia AB 2022 AR2
The report highlights Immunovia's progress in 2022, focusing on the commercialization of its IMMray PanCan-d test for early detection of pancreatic cancer in the US. Key achievements include obtaining Clinical and Public Health Laboratory licenses in almost all US states, receiving accreditation from the College of American Pathologists, and securing a final payment determination of $897 from the Centers for Medicare & Medicaid Services. Additionally, the company established a strategic partnership with Proteomedix to enhance R&D productivity and streamline operations.
Company: Immunovia AB
Sector: Professional & technical services
Country: Sweden
Year: 2022
Type: AR2
Pages: 75
Back to company
Immunovia AB
Annual Report
The report highlights Immunovia's progress in 2022, focusing on the commercialization of its IMMray PanCan-d test for early detection of pancreatic cancer in the US. Key achievements include obtaining Clinical and Public Health Laboratory licenses in almost all US states, receiving accreditation from the College of American Pathologists, and securing a final payment determination of $897 from the Centers for Medicare & Medicaid Services. Additionally, the company established a strategic partnership with Proteomedix to enhance R&D productivity and streamline operations.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2022
Reporting Period
Jan 1, 2022 - Dec 31, 2022
Fiscal Year
2022
Published
Apr 21, 2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Employees